Daratumumab Effective as Adjunctive Maintenance Therapy for Multiple Myeloma | ASH Clinical News | American Society of Hematology
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) induction and consolidation therapy and to lenalidomide maintenance therapy confers a significant benefit to transplant-eligible patients with newly diagnosed (ND) multiple myeloma (MM). Pieter Sonneveld, MD, PhD, professor of hematology at the Erasmus MC Cancer Institute in the Netherlands, reported the improvement in progression-free